Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDA: Rapidity of onset of response to Adalimumab in luminal Crohn's disease
2013-004781-34Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Clinical response at day 4. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2013-004781-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004781-34.